At a glance
ClinicalIndex Comparison RecordN/ACompleted· 140 enrolled
Drug / intervention
Albendazole +1 moredrug
Likely dose
Albendazole 400mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
The Impact of Deworming on Host Immunity and Clinical Outcome in Patients With Pulmonary Tuberculosis
In Brief
A clinical study evaluating Albendazole and Placebo for Tuberculosis. Completed, enrolled 140 participants across 1 site.
Detailed Summary
The purpose of this study is to investigate whether treatment against intestinal helminths in patients with pulmonary tuberculosis undergoing chemotherapy could improve the clinical outcome by enhancing host immunity.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTuberculosis
CountriesEthiopia
Timeline
N/ACompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartMar 2009
First PostedMar 2009
Primary CompletionJun 2013
Study CompletionAug 2013
TodayJul 2026
First PostedMar 6, 2009
Enrollment StartMar 1, 2009
Primary CompletionJun 1, 2013
Study CompletionAug 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 17.3 years ago
Interventions
Albendazoledrug
Albendazole 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis
Placebodrug
Placebo 400mg per os for three consecutive days at week 2 and week 8 after initiation of chemotherapy against tuberculosis